Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. Padrón LJ, et al. Among authors: yu jx. Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3. Nat Med. 2022. PMID: 35662283 Free PMC article. Clinical Trial.
Impact of COVID-19 on oncology clinical trials.
Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2020 Jun;19(6):376-377. doi: 10.1038/d41573-020-00093-1. Nat Rev Drug Discov. 2020. PMID: 32424343 No abstract available.
Cancer cell therapies: the clinical trial landscape.
Yu JX, Upadhaya S, Tatake R, Barkalow F, Hubbard-Lucey VM. Yu JX, et al. Nat Rev Drug Discov. 2020 Sep;19(9):583-584. doi: 10.1038/d41573-020-00099-9. Nat Rev Drug Discov. 2020. PMID: 32457476 No abstract available.
Immuno-oncology drug development forges on despite COVID-19.
Upadhaya S, Hubbard-Lucey VM, Yu JX. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2020 Nov;19(11):751-752. doi: 10.1038/d41573-020-00166-1. Nat Rev Drug Discov. 2020. PMID: 32948858 No abstract available.
The clinical pipeline for cancer cell therapies.
Upadhaya S, Yu JX, Shah M, Correa D, Partridge T, Campbell J. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2021 Jul;20(7):503-504. doi: 10.1038/d41573-021-00100-z. Nat Rev Drug Discov. 2021. PMID: 34088999 No abstract available.
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
Upadhaya S, Neftelino ST, Hodge JP, Oliva C, Campbell JR, Yu JX. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2021 Mar;20(3):168-169. doi: 10.1038/d41573-020-00204-y. Nat Rev Drug Discov. 2021. PMID: 33177720 Review. No abstract available.
COVID-19 impact on oncology clinical trials: a 1-year analysis.
Upadhaya S, Yu JX, Hodge J, Campbell J. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2021 Jun;20(6):415. doi: 10.1038/d41573-021-00086-8. Nat Rev Drug Discov. 2021. PMID: 34002059 No abstract available.
279 results